Litcius/Paper detail

STING Agonist Delivered by Neutrophil Membrane-Coated Gold Nanoparticles Exerts Synergistic Tumor Inhibition with Radiotherapy

Dehua Lu, Wenhua Li, Jingyun Tan, Ying Li, Wei Mao, Yuanyuan Zheng, Muwen Yang, Jin Wang, Weihu Wang, Shubin Wang, Jing Gao, Yajie Liu

2024ACS Applied Materials & Interfaces23 citationsDOI

Abstract

Radiotherapy (RT) is one of the major treatments for cancers and a promising initiator of immune response. Gold nanoparticles are a promising radiosensitizer. In this study, we sought to optimize the drug delivery efficiency of gold nanoparticles and explore their function in delivering stimulator of interferon genes (STING) agonists with or without RT. Gold nanoparticles covalent to MSA-2 (MSA-Au) were mixed with cRGD-modified neutrophil membranes to obtain M-Au@RGD-NM. We explored the treatment efficiency of M-Au@RGD-NM combined with RT. Immune cell regulation and STING pathway activation were detected. We successfully prepared M-Au@RGD-NM with significant tumor suppression by induction of ROS and the resulting DNA damage. In vivo dynamic imaging showed that M-Au@RGD-NM was mainly targeted to radiated tumors. Tumor-bearing mice showed significant tumor inhibition following a combination therapy. M-Au@RGD-NM significantly activated the STING pathway and regulated the whole-body immune response. Locally radiated tumors showed dendritic cells mature, CD8 + T cells upregulation, and M1 polarization, with systematic immune response demonstrated by CD8 + T cell infiltration in abscopal tumors. In this study, we synthesized M-Au@RGD-NM loading MSA-2. Following characterization, we found that RT-based M-Au@RGD-NM treatment achieved good antitumor effects, tumor RT enhancement, and induction of an immune response via STING activation.

Topics & Concepts

Materials scienceStingAgonistNanoparticleColloidal goldRadiation therapyMembraneNanotechnologyCancer researchPharmacologyReceptorMedicineInternal medicineBiochemistryBiologyAerospace engineeringEngineeringinterferon and immune responsesCancer Research and TreatmentsUbiquitin and proteasome pathways